IL13 and eosinophilic esophagitis: A phase two, multicenter, randomized, double-blind, placebo-controlled parallel-group clinical trial (NCT02098473) investigated the role of cendakimab (anti-IL-13 mAb RPC4046) in adults with EoE [30].